Back to Search
DAVID BROWN, MD
MD
Internal Medicine Physician
NPI: 1831292036IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hospitalist Physician
Hospitalist
Code: 208M00000X
01053312A(IN)
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
01053312(IN)
Education
MEDICAL COLLEGE OF WISCONSIN
Class of 1998
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
PMID 24518078·Br J Ophthalmol·2014
4-observational
Aflibercept (eylea) for age-related macular degeneration.
PMID 22354219·Med Lett Drugs Ther·2012
6-review
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
PMID 22300011·Expert Opin Pharmacother·2012
6-review
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
PMID 21526923·N Engl J Med·2011
4-observational
Fundus autofluorescence and visual acuity in central serous chorioretinopathy.
PMID 21055816·Ophthalmology·2011
8-other
Vascular endothelial growth factor Trap-Eye for diabetic macular oedema.
PMID 19174397·Br J Ophthalmol·2009
8-other
Predicted biological activity of intravitreal VEGF Trap.
PMID 18356264·Br J Ophthalmol·2008
4-observational
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
PMID 17386270·Am J Ophthalmol·2007
3-trial
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
PMID 17021319·N Engl J Med·2006
4-observational
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
PMID 16458968·Ophthalmology·2006
5-case
Cystoid macular degeneration in chronic central serous chorioretinopathy.
PMID 12652224·Retina·2003
8-other
VEGF-Trap: a VEGF blocker with potent antitumor effects.
PMID 12177445·Proc Natl Acad Sci U S A·2002
7-preclinical
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
PMID 11927845·Retina·2002
3-trial
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
PMID 19236279·J Infect Dis·2009
3-trial
Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer.
PMID 18622615·Cancer Chemother Pharmacol·2009
8-other
The human papillomavirus type 11 E1--E4 protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope.
PMID 16257432·Virology·2006
8-other
A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women.
PMID 15609227·J Infect Dis·2005
8-other
Intracellular expression patterns of the human papillomavirus type 59 E1/E4 protein in COS cells, keratinocytes, and genital epithelium.
PMID 15564743·Intervirology·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2001 W 86TH ST
INDIANAPOLIS, IN 46260 - Phone
- (317) 338-3634
Quick Facts
- NPI
- 1831292036
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 28
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile